Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
EYEGW was delisted on the 5th of August, 2020.
4 hedge funds and large institutions have $25K invested in Eyegate Pharmaceuticals, Inc. Warrants in 2017 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
25% more capital invested
Capital invested by funds: $20K → $25K (+$5K)
0% more funds holding
Funds holding: 4 → 4 (0)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$753 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
1
AWM Investment Company
New York
| $21K | – | – | – |
|
|
VF
2
Virtu Financial
New York
| $2K | -$753 | -8,190 | -40% |
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $2K | – | – | – |
|
EYEGW Hedge Fund Activity: Q4 2017 in Review
4 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) for Q4 2017, worth a combined $25K — up 25% from $20K a quarter earlier.
Fund positioning in EYEGW was balanced in Q4 2017: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Virtu Financial, cutting an estimated $753.
- 4 institutional investors held Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $25K of Eyegate Pharmaceuticals, Inc. Warrants stock for Q4 2017, up 25% quarter-over-quarter.
- 0 funds opened new Eyegate Pharmaceuticals, Inc. Warrants positions in Q4 2017 and 0 closed out.
- The largest Eyegate Pharmaceuticals, Inc. Warrants seller in Q4 2017 was Virtu Financial, an estimated $753 sold.
Based on aggregated 13F filings for Q4 2017.